AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02305849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral tablet/capsule
Study NCT02305849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral tablet/capsule
Study NCT02882620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity (Group 1)
Description: The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
Study NCT02882620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium Intensity (Group 2)
Description: The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
Study NCT02882620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reference Group (Group 3)
Description: The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
Study NCT04068519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study NCT03062280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Modified release hydrocortisone
Study NCT02957396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finerenone (BAY94-8862): 20 mg intact tablet
Description: 20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
Study NCT02957396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet
Description: 20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
Study NCT02957396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862): 20 mg suspension
Description: 20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
Study NCT04309370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS modulates cortical activation depending on the stimulation parameters used. Physiological studies have provided evidence that suggests that high-frequency (HF) rTMS produces an increase in local cortical excitability. Studies have also demonstrated that rTMS may increase or decrease functional connectivity between separate but related cortical structures, utilizing high and low frequency stimulation, respectively.
Study NCT05302076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity electrical current (LIEC)
Description: Each patient in the electrical group will be asked to wear a removable device containing a small electrical circuit that will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.
Study NCT05302076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional fixed orthodontic appliance
Description: The maxillary arch will be levelled and aligned. The rectangular stainless steel archwires (0.019 × 0.025) with anterior 8mm height soldered hooks distal to the canines will be inserted. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction.
Study NCT02929420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaoru Sanjie capsules
Description: Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
Study NCT01689025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0006
Description: Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
Study NCT01689025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
Study NCT03397303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: elastography measurements
Description: elastography measurements
Study NCT03397303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastography measurements
Description: elastography measurements
Study NCT00366288 — intervention group
Intervention type: DRUG
Intervention: PAZ-417
Description: 2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
Study NCT02821442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients
Study NCT02821442 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Placebo needles appear to penetrate but do not actually penetrate the skin
Study NCT01340625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone/Ethinyl Estradiol
Description: 0.4 mg/35 mcg Chewable Tablets
Study NCT01340625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovcon® 35 Fe
Description: 0.4 mg/35 mcg Chewable Tablets
Study NCT03007160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Citrate Extended-release Tablets
Description: Daily 3.24g, Po ,Tid, each 1.08g/tablets
Study NCT00905073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporin and methotrexate
Description: cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
Study NCT00691821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dressings
Description: Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
Study NCT00691821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])
Description: Participants will receive negative pressure wound therapy.
Study NCT02528071 — intervention group
Intervention type: OTHER
Intervention: Diaphragmatic endurance test
Description: This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion
Study NCT00536198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
Study NCT00536198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
Study NCT04150393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MaaT033 capsule
Description: Oral capsule
Study NCT02403154 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Internal Fixator
Description: Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
Study NCT02403154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Fixator
Description: Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
Study NCT02403154 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: External fixator
Description: External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
Study NCT02403154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External fixator
Description: External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
Study NCT01656473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI and DBT
Description: One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training
Study NCT01656473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI and DBT
Description: Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
Study NCT04216771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin 10mg/m²/day, D1 (IV)
Study NCT04216771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ID cytarabine
Description: Cytarabine 1.5g/m² /12h, D1-D3 (IV)
Study NCT04216771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID cytarabine
Description: Cytarabine 1.5g/m² /12h, D1-D3 (IV)
Study NCT03577691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training for use of web based Decision Aid
Description: Subjects will be guided during a 30 minutes training session to use the website
Study NCT03577691 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No training for use of web based Decision Aid
Description: Subjects will not be guided during a 30 minutes training session to use the website
Study NCT03577691 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pretest surveys and posttest surveys
Description: Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time
Study NCT03577691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pretest surveys and posttest surveys
Description: Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time
Study NCT03577691 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Only posttest surveys
Description: Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
Study NCT03577691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Only posttest surveys
Description: Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
Study NCT04368767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-skin
Description: Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, usually in the afternoon. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. After pre-intervention measures of axillary temperature, heart rate, respiratory rate, and oxygen saturation by pulse oximetry (SPO2) are obtained; cotton balls placed in the diaper for urine collection will be removed and stored in an appropriate container. Salivary oxytocin and cortisol will be collected per protocol below. Mothers will be requested to sit in reclining chairs with a front opened blouse or hospital gown. Infants will be removed from the incubator and placed naked except for a diaper and hat directly onto the skin between the mother's breasts and covered with a blanket. All infants will be monitored. After the two hours of SSC is completed, the infant will be returned to the incubator.
Study NCT04103853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxalutamide
Description: Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
Study NCT01250834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally.
Study NCT01250834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously.
Study NCT04086862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic ultrasound
Description: A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm\^2 and 100% duty cycle sequentially to each masseter muscle.
Study NCT04086862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm\^2 and 100% duty cycle sequentially to each masseter muscle.
Study NCT04531293 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Respiratory Analysis System
Description: Measurement of total lung capacity using total-breath method
Study NCT04531293 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Respiratory Analysis System
Description: Measurement of total lung capacity using standard method
Study NCT03477877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indashyikirwa Couples Training
Description: A training curriculum for heterosexual couples in Rwanda comprising 20 3-hour modules (60 hours total) delivered to groups of 15 couples (30 people). Each module facilitated by male and 1 female facilitator. Curriculum topics include: types and uses of personal and interpersonal power (power within, power over, power with, power to), gender, gender based violence, triggers for intimate partner violence, conflict management, economic development, sexuality, alcohol, social norms and community change. Delivered by RWAMREC.
Study NCT03477877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indashyikirwa Activist Training
Description: This training is offered to a subset of individuals who complete the couples curriculum (randomly selected from among those who are are willing and eligible). These individuals are trained to serve as community activists, teach peers about the types of power (power within, power over, power with, power to), and advocate for community change to prevent intimate partner violence. Delivered by RWAMREC.
Study NCT03477877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indashyikirwa Opinion Leader Training
Description: Training delivered to opinion leaders (political office holders, religious leaders, service providers), in intervention communities. Training comprised 8 x 3 hour sessions (24 hours) delivered for groups of up to 40 participants. Introduces Opinion Leaders to the concepts of power (power within, power over, power with, power to) and to essential concepts around women's legal rights. Delivered by Rwanda Women's Network.
Study NCT03477877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indashyikirwa Women's Spaces
Description: Establishment of 1 Women's Space per intervention sector -- a physical space with trained facilitators on duty from which support and referrals for women experiencing IPV could be offered and ad hoc programming responsive to community needs and interest can be run. Typical activities include once-off open trainings for community members on the concepts of power (power within, power over, power with, power to), essential concepts around women's legal rights, conflict management in families, etc. Delivered by Rwanda Women's Network.
Study NCT03477877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Village Savings and Loan Association (VSLA)
Description: A standard Village Savings and Loan Association program as run nationwide by CARE Rwanda.
Study NCT00667368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
Study NCT03923855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: BTL-899 therapy
Study NCT01765205 — intervention group
Intervention type: DEVICE
Intervention: Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter
Description: Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
Study NCT00499876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mefloquine
Description: 250mg weekly PO for 6 months
Study NCT00499876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet weekly PO for 6 months
Study NCT02301494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.75% Imiquimod Cream
Description: CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
Study NCT02301494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% Fluocinonide Cream
Description: CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
Study NCT02859207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
Study NCT01474057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESTRESS-PC
Description: An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A DESTRESS Nurse will train the participant to use the website and will monitor their progress and report key information back to the primary care physician.
Study NCT01474057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Usual Primary Care PTSD treatment
Description: Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
Study NCT03479268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03479268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03479268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV
Study NCT03479268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT03479268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04692077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir (CAB) tablet
Description: 30 mg tablets
Study NCT04692077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter.
Study NCT04692077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
Description: 300 mg/200 mg fixed-dose combination tablets